{"id":105384,"date":"2025-10-27T08:11:56","date_gmt":"2025-10-27T13:11:56","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/un-nouvel-espoir-dans-la-therapie-ciblee-de-lhistiocytose\/"},"modified":"2025-10-27T08:40:48","modified_gmt":"2025-10-27T13:40:48","slug":"un-nouvel-espoir-dans-la-therapie-ciblee-de-lhistiocytose","status":"publish","type":"post","link":"https:\/\/www.erdheim-chester.org\/fr\/un-nouvel-espoir-dans-la-therapie-ciblee-de-lhistiocytose\/","title":{"rendered":"Un nouvel espoir dans la th\u00e9rapie cibl\u00e9e de l’histiocytose"},"content":{"rendered":"
\n

Une nouvelle \u00e9tude du Memorial Sloan Kettering Cancer Center<\/b> souligne le caract\u00e8re prometteur de l’ulixertinib<\/b>, un m\u00e9dicament de th\u00e9rapie cibl\u00e9e qui bloque ERK, pour traiter certaines formes d’histiocytose,<\/b> notamment la maladie d’Erdheim-Chester (ECD).<\/b><\/span><\/p>\n

Dirig\u00e9e par le Dr Eli Diamond, membre du comit\u00e9 consultatif m\u00e9dical de l’ECDGA, cette recherche marque une \u00e9tape passionnante dans le traitement des troubles histiocytaires induits par les MAPK. Pour de nombreux membres de notre communaut\u00e9, comme Joey, un membre de l’ECDGA dont le parcours continue de nous inspirer, ces perc\u00e9es scientifiques repr\u00e9sentent bien plus qu’un progr\u00e8s clinique. Elles sont porteuses d’espoir. <\/p>\n

Lisez l’article du MSKCC :
\nhttps:\/\/www.mskcc.org\/news\/targeted-therapy-drug-ulixertinib-for-histiocytosis-blood<\/a><\/p>\n

Acc\u00e9dez \u00e0 l’article technique complet dans Cancer Cell<\/i>:
\nhttps:\/\/www.sciencedirect.com\/science\/article\/pii\/S1535610825004064<\/a><\/p>\n

\u00c0 l’ECDGA, nous sommes fiers de soutenir et de partager la recherche qui nous rapproche de meilleurs soins, de plus de r\u00e9ponses et, un jour, d’un rem\u00e8de.<\/p>\n

L’Alliance mondiale contre les maladies Erdheim-Chester Disease Global Alliance (ECDGA) ne fournit pas de conseils m\u00e9dicaux, de diagnostics ou de traitements. Tout le contenu est fourni \u00e0 titre d’information uniquement. Veuillez consulter un prestataire de soins de sant\u00e9 pour toute question d’ordre m\u00e9dical. <\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Une nouvelle \u00e9tude du Memorial Sloan Kettering Cancer Center souligne le caract\u00e8re prometteur de l’ulixertinib, un m\u00e9dicament de th\u00e9rapie cibl\u00e9e qui bloque ERK, pour traiter certaines formes d’histiocytose – dont la maladie d’Erdheim-Chester (ECD).<\/p>\n","protected":false},"author":14,"featured_media":105369,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_wds_title":"","_wds_metadesc":"","_wds_focus-keywords":"","_wds_meta-robots-adv":"","_wds_meta-robots-noindex":false,"_wds_meta-robots-nofollow":false,"_wds_meta-robots-index":false,"_wds_meta-robots-follow":false,"_wds_autolinks-exclude":false,"_wds_canonical":"","_wds_redirect":"","_wds_opengraph":[],"_wds_twitter":[],"cybocfi_hide_featured_image":"","wds_primary_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[426],"tags":[3562,5150,5154,2624,5152,1163,5148,5158,5156,5161,4272,563,5146,5160,5019],"class_list":["post-105384","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ecdga-actualites","tag-cancer-du-sang-rare","tag-cancer-rare-2","tag-chemin-de-la-carte","tag-elidiamond-fr","tag-erdheim-chesterdisease","tag-histiocytose-fr","tag-inhibiteur-derythrocytes","tag-medecine-de-precision-2","tag-memoriauxloankettering","tag-percee-de-la-recherche","tag-recherche-sur-les-maladies-rares","tag-sensibilisation-au-dpe","tag-therapie-ciblee-2","tag-troubles-histiocytaires-2","tag-ulixertinib"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/posts\/105384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/comments?post=105384"}],"version-history":[{"count":0,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/posts\/105384\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/media\/105369"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/media?parent=105384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/categories?post=105384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/tags?post=105384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}